GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: cagrilintide stopped being a problem at week 60 — 69 comments in the full submission. View in context.
2.9k
c/cagrilintide·submitted 2 years ago by u/clara_weiss

small win: cagrilintide stopped being a problem at week 60

Cautionbranch of 6 comments

small win: cagrilintide stopped being a problem at week 60. Numbers below. Ask me the boring questions, they are the useful ones. Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from. Carried an assumption…

Read the full submission and all 69 comments →

This branch

6 comments, started 2 years ago
u/tomas_kimani0 points·2 years ago

Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

replysharereportpermalink
u/freya_baptista1 point·2 years ago

Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

Agreed, and the combination arms are where the interesting numbers actually live.

replysharereportpermalink
u/incretin_ivypharmacology1 point·2 years ago

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

replysharereportpermalink
u/lane_map_larrylogistics1 point·2 years ago·edited

Small fix — amylin analogue, not a GLP-1 analogue.

This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.

replysharereportpermalink
u/hplc_hobbyistruns their own column1 point·2 years ago

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

replysharereportpermalink
u/rekha_mwangi1 point·2 years ago·edited

Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

Adding the standing caveat — nothing here is approved standalone and research material is not for human use.

replysharereportpermalink

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/cagrilintide
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/amylin_amyu/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →